Neda Laiteerapong to Quality-Adjusted Life Years
This is a "connection" page, showing publications Neda Laiteerapong has written about Quality-Adjusted Life Years.
Connection Strength
0.764
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.180
-
Alternative type 2 diabetes screening tests may reduce the number of U.S. adults with undiagnosed diabetes. Diabet Med. 2020 11; 37(11):1935-1943.
Score: 0.154
-
Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
Score: 0.129
-
Impact of delaying blood pressure control in patients with Type 2 diabetes: results of a decision analysis. J Gen Intern Med. 2012 Jun; 27(6):640-6.
Score: 0.086
-
The public health implications of the cost-effectiveness of bariatric surgery for diabetes. Diabetes Care. 2010 Sep; 33(9):2126-8.
Score: 0.078
-
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025 Mar 07; 6(3):e245586.
Score: 0.053
-
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Appl Health Econ Health Policy. 2024 Nov; 22(6):861-869.
Score: 0.052
-
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value Health. 2018 06; 21(6):724-731.
Score: 0.033